Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists

Clinical and Translational Oncology

Volumn 16, Issue 10, 2014, Pages 914-920

  Camps Herrero, C ^a   Paz Ares, L ^b   Codes, M ^c   Lopez Lopez R ^d   Anton Torres A ^e   Gascon Vilaplana P ^f   Guillem Porta, V ^g   Carrato, A ^h   Cruz Hernandez J J ⁱ   Caballero Diaz C ^j   Blasco Cordellat, A ^j   Moreno Nogueira, J A ^b   Diaz Rubio E ^k  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^h HOSPITAL RAMÓN Y CAJAL   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^k HOSPITAL CLÍNICO SAN CARLOS   (Spain)

more..

Author keywords

Cost; New drugs; Oncology; Pharmacoeconomic study

Indexed keywords

COST BENEFIT ANALYSIS; DELPHI STUDY; DRUG COST; DRUG DEVELOPMENT; ECONOMICS; HEALTH PERSONNEL ATTITUDE; HUMAN; NEOPLASMS; ONCOLOGY; PHARMACOECONOMICS; QUALITY ADJUSTED LIFE YEAR; SOCIAL PSYCHOLOGY; SPAIN;

ATTITUDE OF HEALTH PERSONNEL; COST-BENEFIT ANALYSIS; DELPHI TECHNIQUE; DRUG COSTS; DRUG DISCOVERY; ECONOMICS, PHARMACEUTICAL; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; SOCIAL VALUES; SPAIN;

EID: 84929941493     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-014-1170-1     Document Type: Article

References (28)

1. Darba J. Pharmaceutical expenditure and therapeutic value of new medicines in Spain. Pharmacoeconomics. 2003;21(16):1211–2.
2. Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist. 2008;13:19–21.
3. Sargent D. What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions? Oncologist. 2009;15:19–23.
4. Ocaña A, Tannock IF. When are “positive” clinical trials in oncology truly positive? J Natl Cancer Inst. 2011;103:16–20.
5. Sobrero A, Bruzzi P. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J Clin Oncol. 2009;27:5868–73.
6. Stewart DJ, Kurzrock R. Cancer: the road to Amiens. J Clin Oncol. 2009;27:328–33.
7. Fojo T, Grady C. How much is life worth: cetuximab, non-small-cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009;101:1044–8.
8. Fojo T, Parkinson DR. Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin Cancer Res. 2010;16:5972–80.
9. Fojo T, Parkinson DR. Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin Cancer Res. 2010;16:5972–80.
10. López Bastida J, Oliva J, Antoñanzas F, García-Altés A, Gisbert R, Mar J, et al. Propuesta de guía para la evaluación económica aplicada las tecnologías sanitarias. Gac Sanit. 2010; 24(02):154–70.
11. Groose SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8:165–78.
12. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold an what other factors influence its decision? A binary choice analysis. Health Econ. 2004;13:437–52.
13. Bobinac A, Van Exel NJ, Rutten FF, Brouwer WB. Willingness to pay for a quality-adjusted life-year: the individual perspective. Val Health. 2010;13:1046–55.
14. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained. What is the threshold of cost-effectiveness? Health Econ. 2010;19:422–37.
15. Cleemput I, Neyt M, Thiry N, De Laet C, Leys M. Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions. Int J Health Technol Assess Health Care. 2011;27:71–6.
16. Bobinac A, van Exel NJ, Rutten FF, Brouwer WB. Inquiry into the relationship between equity weights and the value of the QALY. Val Health. 2012; 1119–26.
17. Donaldson C, Baker R, Mason H, Jones-Lee M, Lancsar E, Wildman J, et al. The social value of a QALY: raising the bar or barring the raise? BMC Health Serv Res. 2011;11:8.
18. Pinto-Prades JL, Loomes G, Brey R. Trying to estimate a monetary value for the QALY. J Health Econ. 2009;28:553–62.
19. Zhao FL, Yue M, Yang H, Wang T, Wu JH, Li SC. Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making? Med Care. 2011;49:267–72.
20. Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL. ¿Qué es una tecnología sanitaria eficiente en España? Gac Sanit. 2002;16:334–43.
21. Prieto L, Sacristán JA, Antoñanzas F, Rubio-Terrés C, Pinto JL, Rovira J. Análisis coste-efectividad en la evaluación económica de intervenciones sanitarias. Med Clin (Barc). 2004;122(13):505–10.
22. Camps C, Caballero C, Sirera R, Blasco A, Cayuela D, Gil M, et al. Can the Spanish care system assume the new costs of medications against cancer? Clin Transl Oncol. 2008;10(2):96–101.
23. Isla D, González-Rojas N, Nieves D, Brosa M, Finnern HW. Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel. Clin Transl Oncol. 2011;13:460–71.
24. Oyagüez I, Frías C, Seguí MA, Gómez-Barrera M, Casado MA, Queralt Gorgas M. Eficiencia de tratamientos oncológicos para tumores sólidos en España. Farm Hosp. 2013;37:240–59.
25. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium—the just price. J Clin Oncol. 2013;28:3600–4.
26. Tsimberidou AM, Ringborg U, Schilsky RL. Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine. Am Soc Clin Oncol Educ Book. 2013:118–25. doi:10.1200/EdBook_AM.2013.33.118.
27. Pfister DG. The just price of cancer drugs and the growing cost of cancer care: oncologists need to be part of the solution. J Clin Oncol. 2013;28:3487–9.
28. Piccart MJ. Why your preferred targeted drugs may become unaffordable. Cancer Res. 2013;73:5849–51.